Access cutting-edge aml treatment through this clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.
Access aml specialists in Little Rock at no cost
This study follows strict safety protocols and ethical guidelines
All study-related aml treatment provided free
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of
Sponsor: Children's Oncology Group
Check if you qualify for this aml clinical trial in Little Rock, AR
If you're searching for aml treatment options in Little Rock, AR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Little Rock research site is actively enrolling participants for this clinical trial. You'll receive care from experienced aml specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.